Skip to Main Content

Paper Details

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
J Immunother Cancer
16
2019
Author NameAffiliation
Eneida A MendoncaUniversity of Wisconsin
Eneida A MendoncaUniversity of Wisconsin
  • 1 - 2

Datasets

Release 1.2